Does the media favor RVMD or CYTK?

In the previous week, Revolution Medicines had 14 more articles in the media than Cytokinetics. MarketBeat recorded 22 mentions for Revolution Medicines and 8 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.97 beat Revolution Medicines' score of 0.29 indicating that Cytokinetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 10 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cytokinetics 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ONC or CYTK?

In the previous week, BeOne Medicines had 3 more articles in the media than Cytokinetics. MarketBeat recorded 11 mentions for BeOne Medicines and 8 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.97 beat BeOne Medicines' score of -0.18 indicating that Cytokinetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cytokinetics 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BNTX or CYTK more profitable?

BioNTech has a net margin of -44.39% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat BioNTech's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -44.39% -5.30% -4.62% Cytokinetics -784.02% N/A -52.86%

Does the media refer more to BNTX or CYTK?

In the previous week, Cytokinetics had 5 more articles in the media than BioNTech. MarketBeat recorded 8 mentions for Cytokinetics and 3 mentions for BioNTech. Cytokinetics' average media sentiment score of 0.97 beat BioNTech's score of 0.85 indicating that Cytokinetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CYTK or ROIV?

In the previous week, Cytokinetics and Cytokinetics both had 8 articles in the media. Roivant Sciences' average media sentiment score of 1.49 beat Cytokinetics' score of 0.97 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, CYTK or INSM?

Cytokinetics has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cytokinetics $88.04M 112.34 -$784.96M -$6.84 N/A Insmed $606.42M 36.41 -$1.28B -$5.75 N/A

Is CYTK or INSM more profitable?

Insmed has a net margin of -144.44% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Cytokinetics -784.02% N/A -52.86% Insmed -144.44% -130.11% -51.57%

Does the media favor CYTK or INSM?

In the previous week, Insmed had 5 more articles in the media than Cytokinetics. MarketBeat recorded 13 mentions for Insmed and 8 mentions for Cytokinetics. Insmed's average media sentiment score of 1.32 beat Cytokinetics' score of 0.97 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cytokinetics (CYTK) Competitors

$79.07 -0.10 (-0.13%)

As of 02:26 PM Eastern

Compare

CYTK vs. RVMD, ONC, BNTX, ROIV, and INSM

Should you buy Cytokinetics stock or one of its competitors? MarketBeat compares Cytokinetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cytokinetics include Revolution Medicines (RVMD), BeOne Medicines (ONC), BioNTech (BNTX), Roivant Sciences (ROIV), and Insmed (INSM). These companies are all part of the "pharmaceutical products" industry.

How does Cytokinetics compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

Revolution Medicines has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

In the previous week, Revolution Medicines had 14 more articles in the media than Cytokinetics. MarketBeat recorded 22 mentions for Revolution Medicines and 8 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.97 beat Revolution Medicines' score of 0.29 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	10 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytokinetics	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytokinetics has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,097.06	-$1.13B	-$7.07	N/A
Cytokinetics	$88.04M	112.34	-$784.96M	-$6.84	N/A

Revolution Medicines has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Cytokinetics	-784.02%	N/A	-52.86%

Revolution Medicines presently has a consensus target price of $123.72, indicating a potential downside of 26.66%. Cytokinetics has a consensus target price of $99.30, indicating a potential upside of 24.93%. Given Cytokinetics' higher probable upside, analysts plainly believe Cytokinetics is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86

94.3% of Revolution Medicines shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by company insiders. Comparatively, 2.6% of Cytokinetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Revolution Medicines beats Cytokinetics on 9 of the 17 factors compared between the two stocks.

How does Cytokinetics compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

In the previous week, BeOne Medicines had 3 more articles in the media than Cytokinetics. MarketBeat recorded 11 mentions for BeOne Medicines and 8 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.97 beat BeOne Medicines' score of -0.18 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytokinetics	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines presently has a consensus price target of $390.00, suggesting a potential upside of 41.67%. Cytokinetics has a consensus price target of $99.30, suggesting a potential upside of 24.93%. Given BeOne Medicines' stronger consensus rating and higher probable upside, analysts clearly believe BeOne Medicines is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86

BeOne Medicines has a net margin of 8.94% compared to Cytokinetics' net margin of -784.02%. BeOne Medicines' return on equity of 12.06% beat Cytokinetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Cytokinetics	-784.02%	N/A	-52.86%

BeOne Medicines has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	5.65	$286.93M	$4.47	61.59
Cytokinetics	$88.04M	112.34	-$784.96M	-$6.84	N/A

48.6% of BeOne Medicines shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by insiders. Comparatively, 2.6% of Cytokinetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BeOne Medicines has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

Summary

BeOne Medicines beats Cytokinetics on 13 of the 16 factors compared between the two stocks.

How does Cytokinetics compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

BioNTech has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

In the previous week, Cytokinetics had 5 more articles in the media than BioNTech. MarketBeat recorded 8 mentions for Cytokinetics and 3 mentions for BioNTech. Cytokinetics' average media sentiment score of 0.97 beat BioNTech's score of 0.85 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytokinetics has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.07	-$1.29B	-$5.88	N/A
Cytokinetics	$88.04M	112.34	-$784.96M	-$6.84	N/A

BioNTech presently has a consensus price target of $129.56, indicating a potential upside of 42.68%. Cytokinetics has a consensus price target of $99.30, indicating a potential upside of 24.93%. Given BioNTech's higher probable upside, analysts plainly believe BioNTech is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86

BioNTech has a net margin of -44.39% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Cytokinetics	-784.02%	N/A	-52.86%

15.5% of BioNTech shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 2.6% of Cytokinetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Cytokinetics beats BioNTech on 9 of the 17 factors compared between the two stocks.

How does Cytokinetics compare to Roivant Sciences?

Cytokinetics (NASDAQ:CYTK) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

In the previous week, Cytokinetics and Cytokinetics both had 8 articles in the media. Roivant Sciences' average media sentiment score of 1.49 beat Cytokinetics' score of 0.97 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytokinetics has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

64.8% of Roivant Sciences shares are held by institutional investors. 2.6% of Cytokinetics shares are held by insiders. Comparatively, 10.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cytokinetics currently has a consensus target price of $99.30, suggesting a potential upside of 24.93%. Roivant Sciences has a consensus target price of $33.59, suggesting a potential upside of 6.47%. Given Cytokinetics' stronger consensus rating and higher probable upside, research analysts plainly believe Cytokinetics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Roivant Sciences has lower revenue, but higher earnings than Cytokinetics. Roivant Sciences is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	112.34	-$784.96M	-$6.84	N/A
Roivant Sciences	$8.26M	2,747.25	-$299.77M	-$0.60	N/A

Cytokinetics has a net margin of -784.02% compared to Roivant Sciences' net margin of -3,629.19%. Cytokinetics' return on equity of 0.00% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

Summary

Cytokinetics and Roivant Sciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Cytokinetics compare to Insmed?

Cytokinetics (NASDAQ:CYTK) and Insmed (NASDAQ:INSM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

Cytokinetics has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Insmed has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

Cytokinetics has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	112.34	-$784.96M	-$6.84	N/A
Insmed	$606.42M	36.41	-$1.28B	-$5.75	N/A

Insmed has a net margin of -144.44% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Insmed	-144.44%	-130.11%	-51.57%

Cytokinetics currently has a consensus target price of $99.30, suggesting a potential upside of 24.93%. Insmed has a consensus target price of $211.86, suggesting a potential upside of 107.99%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

In the previous week, Insmed had 5 more articles in the media than Cytokinetics. MarketBeat recorded 13 mentions for Insmed and 8 mentions for Cytokinetics. Insmed's average media sentiment score of 1.32 beat Cytokinetics' score of 0.97 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Insmed beats Cytokinetics on 10 of the 15 factors compared between the two stocks.

Get Cytokinetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYTK vs. The Competition

Export

Metric	Cytokinetics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.89B	$3.49B	$6.49B	$12.17B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-11.62	20.23	24.68	24.05
Price / Sales	112.34	333.33	530.15	111.08
Price / Cash	N/A	56.54	27.92	37.84
Price / Book	-14.75	8.34	10.87	6.56
Net Income	-$784.96M	$23.85M	$3.56B	$336.88M
7 Day Performance	5.68%	5.68%	1.99%	0.06%
1 Month Performance	3.31%	2.63%	0.74%	1.07%
1 Year Performance	143.51%	61.83%	33.47%	32.09%

Cytokinetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYTK Cytokinetics	3.5824 of 5 stars	$79.07 -0.1%	$99.30 +25.6%	+144.1%	$9.84B	$88.04M	N/A	250
RVMD Revolution Medicines	1.6697 of 5 stars	$160.06 +4.0%	$123.72 -22.7%	+318.1%	$32.71B	$11.58M	N/A	250	Positive News
ONC BeOne Medicines	4.1417 of 5 stars	$268.20 +1.4%	$390.00 +45.4%	+10.0%	$29.02B	$5.34B	60.00	12,000	Analyst Downgrade
BNTX BioNTech	4.5365 of 5 stars	$90.80 +0.3%	$129.56 +42.7%	-15.3%	$22.90B	$3.25B	N/A	7,807
ROIV Roivant Sciences	2.0559 of 5 stars	$30.03 0.0%	$33.59 +11.9%	+172.9%	$21.61B	$8.26M	N/A	860	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYTK) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytokinetics (CYTK) Competitors

CYTK vs. RVMD, ONC, BNTX, ROIV, and INSM

How does Cytokinetics compare to Revolution Medicines?

Summary

How does Cytokinetics compare to BeOne Medicines?

Summary

How does Cytokinetics compare to BioNTech?

Summary

How does Cytokinetics compare to Roivant Sciences?

Summary

How does Cytokinetics compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK vs. The Competition

Cytokinetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytokinetics (CYTK) Competitors

CYTK vs. RVMD, ONC, BNTX, ROIV, and INSM

How does Cytokinetics compare to Revolution Medicines?

Which has more volatility & risk, RVMD or CYTK?

Does the media favor RVMD or CYTK?

Which has better earnings and valuation, RVMD or CYTK?

Is RVMD or CYTK more profitable?

Do analysts prefer RVMD or CYTK?

Do institutionals & insiders believe in RVMD or CYTK?

Summary

How does Cytokinetics compare to BeOne Medicines?

Does the media refer more to ONC or CYTK?

Do analysts recommend ONC or CYTK?

Is ONC or CYTK more profitable?

Which has stronger earnings & valuation, ONC or CYTK?

Do institutionals and insiders hold more shares of ONC or CYTK?

Which has more volatility & risk, ONC or CYTK?

Summary

How does Cytokinetics compare to BioNTech?

Which has more volatility & risk, BNTX or CYTK?

Does the media refer more to BNTX or CYTK?

Which has better earnings and valuation, BNTX or CYTK?

Do analysts rate BNTX or CYTK?

Is BNTX or CYTK more profitable?

Do insiders & institutionals believe in BNTX or CYTK?

Summary

How does Cytokinetics compare to Roivant Sciences?

Does the media favor CYTK or ROIV?

Which has more volatility and risk, CYTK or ROIV?

Do insiders and institutionals hold more shares of CYTK or ROIV?

Do analysts rate CYTK or ROIV?

Which has stronger earnings and valuation, CYTK or ROIV?

Is CYTK or ROIV more profitable?

Summary

How does Cytokinetics compare to Insmed?

Which has more risk & volatility, CYTK or INSM?

Which has preferable valuation and earnings, CYTK or INSM?

Is CYTK or INSM more profitable?

Do analysts rate CYTK or INSM?

Does the media favor CYTK or INSM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK vs. The Competition

Cytokinetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools